CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The project focuses on developing innovative gene therapy for sensorineural hearing loss, particularly targeting Usher syndrome. By utilizing advanced lentiviral vectors, it aims to deliver large genetic payloads effectively, paving the way for clinical trials and potential treatments that address both hearing loss and…
The most prevalent genetic sensory defect, sensorineural hearing loss (SNHL), affects >430 million people and results in substantial financial and social consequences.
Current treatment options are limited, achieving only temporary or partial relief and are restricted to a sub-group of patients.
Therefore, novel treatment options are of high clinical need.
Genetic mutations play a role in the majority of SNHL cases, which makes SNHL an ideal setting for innovative clinical gene therapy approache…
MEDIZINISCHE HOCHSCHULE HANNOVER
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
